Pfizer, BioNTech, Moderna Lose Bid to Dismiss Bayer's mRNA Patent Lawsuit

Pfizer, BioNTech, and Moderna must face a patent infringement lawsuit from Bayer AG's Monsanto unit after a federal judge in Delaware on Monday denied their motion to dismiss the case. The lawsuit alleges the companies' widely used COVID-19 vaccines utilized messenger RNA (mRNA) technology patented by Monsanto.

The Court's Decision

In the ruling, U.S. Circuit Judge William Bryson determined that the vaccine manufacturers had not sufficiently demonstrated, at this preliminary stage of litigation, that the patent was invalid or that their products did not infringe upon it. The decision means the case, which Bayer filed in January, will now move forward into the discovery phase.

The vaccine makers had argued that their manufacturing processes differ significantly from the technology described in Bayer's patent. Moderna had also made the additional claim that the patent in question covered an unpatentable "law of nature."

Background of the Dispute

Bayer's lawsuit centers on technology it claims Monsanto developed in the 1980s, originally for the purpose of strengthening mRNA in crops. The German conglomerate alleges this same foundational technology was used by the defendants to stabilize the genetic material in their highly successful COVID-19 vaccines.

Ad

This legal battle is one of several high-stakes patent disputes involving the lucrative mRNA platform, which proved critical during the global pandemic and holds promise for future therapies. According to the report, representatives for Pfizer, BioNTech, and Moderna did not immediately respond to requests for comment.

What It Means for Investors

Monday's ruling is a procedural setback for the vaccine developers, ensuring the patent dispute will continue, likely adding to their legal costs. While the decision is not a final judgment on the merits of Bayer's claims, it prolongs the legal uncertainty surrounding a key technology for the pharmaceutical giants.

Key points for the market include:

• Prolonged Litigation: The case will now proceed, representing a lingering financial and operational risk for the three companies.
• Potential Financial Impact: A future verdict or settlement in Bayer's favor could result in significant damages or force the vaccine makers into royalty payment agreements.
• Intellectual Property Landscape: The outcome could have broader implications for the complex and competitive intellectual property landscape for mRNA-based medicines.